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STUDY PROTOCOL Open Access
Implementing universal Lynch syndrome
screening (IMPULSS): protocol for a multi-
site study to identify strategies to
implement, adapt, and sustain genomic
medicine programs in different
organizational contexts
Alanna Kulchak Rahm1* , Deborah Cragun2, Jessica Ezzell Hunter3, Mara M. Epstein4, Jan Lowery5, Christine Y. Lu6,
Pamala A. Pawloski7, Ravi N. Sharaf8, Su-Ying Liang9, Andrea N. Burnett-Hartman10, James M. Gudgeon11,
Jing Hao12, Susan Snyder12, Radhika Gogoi1, Ilene Ladd1 and Marc S. Williams1
Abstract
Background: Systematic screening of all colorectal tumors for Lynch Syndrome (LS) has been recommended since
2009. Currently, implementation of LS screening in healthcare systems remains variable, likely because LS screening
involves the complex coordination of multiple departments and individuals across the healthcare system. Our
specific aims are to (1) describe variation in LS screening implementation across multiple healthcare systems; (2)
identify conditions associated with both practice variation and optimal implementation; (3) determine the relative
effectiveness, efficiency, and costs of different LS screening protocols by healthcare system; and (4) develop and
test in a real-world setting an organizational toolkit for LS screening program implementation and improvement.
This toolkit will promote effective implementation of LS screening in various complex health systems.
Methods: This study includes eight healthcare systems with 22 clinical sites at varied stages of implementing LS
screening programs. Guided by the Consolidated Framework for Implementation Research (CFIR), we will conduct
in-depth semi-structured interviews with patients and organizational stakeholders and perform economic evaluation
of site-specific implementation costs. These processes will result in a comprehensive cross-case analysis of different
organizational contexts. We will utilize qualitative data analysis and configurational comparative methodology to
identify facilitators and barriers at the organizational level that are minimally sufficient and necessary for optimal LS
screening implementation.
(Continued on next page)
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Discussion: The overarching goal of this project is to combine our data with theories and tools from implementation
science to create an organizational toolkit to facilitate implementation of LS screening in various real-world settings.
Our organizational toolkit will account for issues of complex coordination of care involving multiple stakeholders to
enhance implementation, sustainability, and ongoing improvement of evidence-based LS screening programs.
Successful implementation of such programs will ultimately reduce suffering of patients and their family members
from preventable cancers, decrease waste in healthcare system costs, and inform strategies to facilitate the promise of
precision medicine.
Trial registration: N/A
Keywords: Lynch syndrome, Implementation, Qualitative comparative analysis (QCA), Consolidated framework for
implementation research (CFIR), Precision medicine, Universal screening, Colorectal Cancer, Economic evaluation,
Decision analytic modeling, Configurational comparative method
Background
Rationale
The goal of precision medicine is to improve health
outcomes by tailoring healthcare based on an individual’s
genomic and other relevant information, including patient
preferences [1]. One example is systematic screening of
colorectal cancer (CRC) tumors to identify all patients
whose CRC may be related to Lynch syndrome (LS) [2, 3].
LS is the most common form of inherited CRC and is also
associated with significant risk for endometrial, ovarian,
gastric, small bowel, and renal cancers, among others [4, 5].
LS most commonly results from the inactivation of the
DNA mismatch repair (MMR) system. A first step in
screening for LS in patients with cancer involves testing
tumor tissue for signs of MMR deficiency in one of four
genes (MLH1, MLH2, MLH6, and PMS2) [2]. Following a
positive tumor screening test, additional testing for the
presence of a germline pathogenic variant in one of the
MMR genes is needed to confirm diagnosis of LS. A diag-
nosis of LS influences cancer screening and surveillance
guidelines to be followed and treatment options for those
already diagnosed with cancer. Patients with CRC who have
LS benefit from treatment with immunotherapy [6] and
have the option for more extensive colonic surgery to
decrease the risk of metachronous malignancy, which is
more common in LS [4, 5]. Additionally, prophylactic
hysterectomy, and salpingoophorectomy can reduce
risk of endometrial and ovarian cancer (90–100%) in
women with LS [7].
Approximately one million people in the US have LS,
of which only about 2% are aware [8, 9]. Therefore, most
are not receiving potentially life-saving surveillance and
treatment. In addition, at-risk family members, who are
at 50% risk to also have LS, are not being identified.
Cost-effective, evidence-based systematic screening strat-
egies to identify cancer patients with LS are available
and have broad recommendation for implementation [2,
10–16], yet LS screening is inconsistently applied within
healthcare systems, if at all [17–19]. Systematic (also
called, “universal”) screening of all newly diagnosed
cases of CRC for LS is cost-effective by most measures
[20, 21] and is classified by the Centers for Disease
Control (CDC) as having top-tier evidence for reducing
cancer morbidity and mortality and improving quality of
life [11, 22]. LS screening was first recommended by the
Evaluation of Genetic Application in Practice and
Prevention (EGAPP) working group in 2009, and is
currently recommended by multiple professional organi-
zations, including the National Comprehensive Cancer
Network (NCCN), and the Healthy People 2020 initia-
tive [3, 10, 12–16, 23]. LS screening was also recently
recommended by the Blue Ribbon Panel Precision
Prevention and Early Detection Working Group to meet
the goals of the Cancer Moonshot [9].
Contextual factors such as organization mission, patient
population, and costs may all influence decisions to imple-
ment genomic technologies in healthcare systems [17, 24–
27]. However, there is poor understanding of how these
and other contextual factors impede or facilitate LS
screening implementation in healthcare systems and
under what circumstances [17, 18]. Factors specific to LS
screening implementation may include: variable involve-
ment of multiple key stakeholders and champions, avail-
ability of genetic counseling, genetic testing costs, and
perception of value to the healthcare system [18, 19, 28].
Previous research has shown that institutional testing
costs, number of CRC patients diagnosed per year, local
prevalence of LS, and perceived cost of screening older
cancer patients are key determinants for organizational
decision makers and likely key barriers to LS screening
implementation [28–30]. Additionally, there are multiple
evidence-based protocols that provide different recom-
mendations for LS screening [4, 10, 31]. These conflicting
recommendations are not surprising in the face of evolv-
ing evidence, but they are likely contributors to variability
in implementation. For instance, the NCCN guidelines
suggest that if all CRCs cannot be tested, then testing
should occur on tumors of patients diagnosed under age
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70 and for patients with CRC over age 70 who meet com-
plex criteria using family history or tumor characteristics
associated with increased LS risks [4, 15]. This conflicts
with evidence demonstrating that imposing age restric-
tions can result in substantive loss of LS index case find-
ing, is challenging to implement, and assessment of family
history and other risk factors often fails to identify individ-
uals who are appropriate candidates for LS testing [8, 32].
However, LS screening is only successful if patients who
screen positive (by tumor tissue testing) are informed and
follow-through with confirmatory germline testing so that
patients and their family members can access appropriate
cancer treatment, screening, and prevention options. A
functional tracking system and/or other processes to en-
sure program success is therefore an additional component
of critical importance to LS screening. A study of several
medical centers found that positive results were often not
disclosed and poor rates of patient follow-through to germ-
line confirmation occurred until such procedures were in-
cluded in LS screening programs [19]. Finally, healthcare
systems vary in implementation across a spectrum from no
organized LS screening to optimal LS screening. The latter
is defined as including implementation or maintenance of
cost-effective tumor screening protocols, procedures to
ensure disclosure of positive screening, and active
processes to facilitate patient follow-through to germline
genetic testing for diagnosis of LS [33–35]. An additional
file shows a typical optimal LS screening program design
[see Additional file 1].
Guiding framework
Due to the complexity of LS screening and the vari-
ability of healthcare systems in which screening is to
be implemented, a systematic approach based on the
principles of implementation science is needed to
ensure the success and sustainability of LS screening
programs. The Consolidated Framework for Imple-
mentation Research (CFIR) has been used successfully
to evaluate variation in program implementation [36,
37] and to identify conditions necessary for patient
follow-through to confirmatory gene sequencing in LS
screening programs [19]. The CFIR describes several
processes that may influence implementation success
and guides assessment of contextual conditions that
may serve as implementation barriers or facilitators at
the individual, organizational, and external levels. The
CFIR also guides data gathering and structuring for
conducting configurational comparative analysis to
identify which CFIR constructs and LS screening
program-specific procedures are minimally sufficient
and necessary for optimal implementation, and under
which circumstances in complex health care delivery
systems [19, 38, 39].
Objectives and aims
The goal of this project is to utilize the CFIR and other
tools from implementation science to describe, compare,
and explain variations in LS screening across multiple
healthcare systems and create a comprehensive,
customizable organizational toolkit for implementing
and improving LS screening programs. To achieve this
goal, this study has four specific aims:
Aim 1: Describe variations in LS screening, implementa-
tion processes, and contextual conditions facilitating or im-
peding implementation across multiple healthcare systems.
Aim 2: Explain current practice variation and identify
contextual conditions that influence variation in LS screen-
ing, including follow-up procedures, and implementation
processes to identify which combinations are minimally
sufficient and necessary for optimal implementation.
Aim 3: Determine the relative effectiveness and costs of
different LS screening protocols using decision analytic
models developed from previous work [29, 30] and data
specific to each healthcare system to demonstrate the rela-
tive effectiveness and efficiency of various LS screening pro-
tocols used by healthcare systems based on their local data.
Aim 4: Develop an organizational toolkit to facilitate LS
screening implementation and optimization and dissemin-
ate to all sites. Further assess the toolkit’s utility for facili-
tating LS screening implementation or optimization then
refine and for broader dissemination.
Methods/design
Overall study design
This study combines multiple methods of exploring imple-
mentation in complex healthcare systems to determine
which implementation strategies are likely to work best in
different organizational contexts. We will use traditional
case-based, in-depth analyses of conditions that may serve
as barriers and facilitators of LS screening (Aim 1), followed
by cross-case and configurational comparative analysis to
determine minimally sufficient and necessary conditions for
optimal LS screening (Aim 2). These data will be used to
populate economic evaluation decision analytic models to
demonstrate how organizational context, available re-
sources, and screening protocol impact organizational costs
and program success (Aim 3). A toolkit will be created and
disseminated to sites to guide implementation of new pro-
grams that are aligned with the organizational context and
costs or to optimize existing programs (Aim 4).
Study setting
The unit of analysis is the clinical site through which LS
screening is or can be implemented. We will study the
contextual factors of 21 clinical sites across 7 healthcare
systems purposively selected to maximize the number of
clinical sites in various stages of implementing LS screen-
ing, as well as to maximize diversity of location, system
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structures, and patient populations (Table 1). Six health-
care systems (Kaiser Permanente Northwest and Color-
ado, HealthPartners, Harvard Pilgrim Healthcare, Meyers
Primary Care Institute/Reliant Medical Group, Sutter
Health-Palo Alto Medical Research Foundation, and
Geisinger) are part of the Healthcare Systems Research
Network (HCSRN), and one is a national non-profit
faith-based system with locations in 18 states (Catholic
Health Initiatives). Of the six HCSRN sites, Kaiser Perma-
nente sites are integrated healthcare systems where
patients are members, while the other sites are “open” sys-
tems where patients can be members, patients, or patient
members (e.g. members receiving care in the system or
outside the system, or patients receiving care who are not
members of the health plan).
Data collection aims 1 and 2
A comprehensive case description of each organization,
including practice variation and factors influencing
implementation, evaluation, maintenance, and improve-
ment of LS screening, will be created through qualitative
interviews of organizational stakeholders and patients with
newly diagnosed CRC. For sites with LS screening pro-
grams, additional interviews will be conducted with pa-
tients diagnosed with LS. Interviews of organizational
stakeholders will be conducted centrally by trained staff at
Geisinger. Interviews of patients will be conducted centrally
by trained staff at Kaiser Permanente Northwest (KPNW).
Consent will be obtained at the start of the interview
process and patient interviewees will receive a $25 gift card
upon completion of the interview.
Organizational stakeholder recruitment
Up to 10 organizational stakeholders per site will be
recruited through purposive role-based recruitment and
snowball sampling [40, 41]. The actual number of and
specific key stakeholders interviewed will depend on the
site’s organizational structure. Typical stakeholders relevant
Table 1 Participating Healthcare Systems and Lynch Syndrome Screening by Clinical Site
Lynch Syndrome Screening Program Typea
CRC Tumor Screeningb EC Tumor Screeningc
Healthcare System Clinical Site (State) No Program CRC age cutoff BRAF Reflex PHM Reflex EC age cutoff PHM Reflex
Geisinger Geisinger (PA) All ages X X All ages X
Kaiser Permanente (KP) KP-Colorado (CO) X
KP-Northwest (OR/WA) All ages X X All ages X
Sutter Health (SH) SH-Palo Alto Medical
Foundation (CA)
X
Meyers Primary Care
Institute (MCPI)
Reliant Medical Group (MA) All ages
HealthPartners HealthPartners (MN) All ages X X All ages X
Harvard Pilgrim
Healthcare
Harvard Pilgrim (MA) X
Catholic Health
Initiatives (CHI)
Franciscan (WA) All ages X X All ages X
Tri Health (OH) All ages X X All ages X
Mercy Des Moines (IA) All ages X X All ages
Kentucky One (KY) All ages
Chattanooga (TN) All ages X X All ages X
Good Samaritan (NE) X
Lincoln (NE) < 70 years X
St. Francis (NE) X
St. Joes Bryan (TX) X
St. Vincent (AR) X
Centura (CO) < 70 years < 60 years
Alegent Creighton (OH) X
St. Alexius (ND) X
Mercy (ND) X
aRecommendation: screen all Colorectal cancer (CRC) and Endometrial Cancer (EC) tumors for mismatch repair deficiency
bRecommendation: reflex test positive screens for BRAFV600E point mutation and MLH1 Promoter Hypermethylation (PHM) testing to rule out somatic loss of
function (sporadic cancer)
cRecommendation: reflex test positive screens for PHM to rule out somatic loss of function (sporadic cancer)
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to LS screening include: pathologists, genetic counselors,
gastroenterologists, oncologists, surgeons, healthcare
administrators, and health plan leaders. Research staff from
each site will reach out to initial stakeholders from their
organization via email or other methods to alert them to
the study and invite them to participate in a telephone
interview. At the end of each completed interview, the
interviewee will be asked to identify any additional
organizational stakeholders necessary for implementing
new processes generally and LS screening specifically
(snowball sampling). Additional stakeholders will be sent
an email indicating that they were nominated to be invited
into the study and offered the opportunity to participate in
a telephone interview.
Patient stakeholder recruitment
Consideration of patient needs is another CFIR construct
that may impact implementation success; therefore, it is
critical to gather their feedback about LS screening.
Patient follow-through with germline confirmation of LS
is required for tumor screening to impact downstream
clinical care processes. Likewise, anticipation of adverse
patient reactions by organizational decision-makers can
be a barrier to implementation at the system level. Two
different groups of patient stakeholders will be invited to
participate in this study: [1] patients newly diagnosed with
CRC (N = 10 per site) and [2] patients who have been
notified of a positive LS screen result and were recom-
mended for additional genetic counseling and testing to
confirm a diagnosis (N = 25 total across all sites with LS
screening). For patients with newly diagnosed CRC, study
staff at each site will determine the best way to identify
and contact patients 3–6 months post-diagnosis and offer
the opportunity to participate in this one-time telephone
interview. This group will illuminate local patient attitudes
and opinions about LS screening for organizational
decision-makers, while the diversity of these patients
across all sites will provide insight into patient attitudes in
general towards LS screening. Patients who have received
a positive LS screen result will provide insight into patient
experiences with a positive LS screen across different sites
and different LS screening protocols.
Qualitative data collection
Based on prior work [19, 40–42], it is anticipated that
most organizational stakeholders will participate in inter-
views, resulting in sufficient information from each site to
create a comprehensive case description with consistent
detail for comparison across sites. While the number of
patients interviewed per site is small (n = 10), the total
number of patients across all sites (n = 220) is large for
qualitative research and will result in sufficient sample size
to capture the range of experiences, expectations, and
preferences of newly diagnosed cancer patients from
diverse backgrounds and healthcare systems related to LS
screening.
As used previously by this research team and others,
semi-structured interviews will be conducted via tele-
phone centrally as noted above by staff experienced in
qualitative data collection [40–44]. A summary will be
created immediately after each interview and reviewed
with site investigators during regular study meetings.
These summaries will be used to modify the sampling
procedure or interview guides if needed, to create the
initial coding schema, and to create the comprehensive
case description of each organization. Such summaries
allow for high-level analysis during on-going data collec-
tion, facilitate codebook development, and reduce the
number of de novo codes requiring re-review and
re-coding of transcripts during data analysis [45, 46].
The CFIR-guided constructs to be assessed through the
organizational and patient stakeholder interview guides are
detailed in Table 2. The organizational stakeholder inter-
view guide has been developed and refined using the ques-
tion bank available from the CFIR website [47] and will be
further tailored to the position of the key stakeholder. For
example, system leaders may be asked more questions
about engagement of leadership, external influences, and
reimbursement incentives [40]. The patient interview guide
has been adapted from a prior study [44].
Data analyses aims 1 and 2
We will use CFIR and the case summaries created for
each site to guide cross-case comparisons with the
Table 2 CFIR Constructs by Domain Specific to LS Screening to
be Assessed in Stakeholder Interviews
CFIR Domain CFIR Constructs Specific to LS Screening
Intervention
Characteristics
Adaptability of LS screening to local context
Perceived difficulty implementing LS screening
Cost to the organization associated with screening
Outer Setting Patient needs and resources
Competitive pressure to implement screening
Impact of external policies on organization
Inner Setting Organization structure
Perceived organizational priority to implement
Implementation climate in organization
Characteristics
of Individuals
LS knowledge and beliefs, perceptions of
evidence
Individual readiness to implement screening
Self-efficacy to complete actions in screening
Implementation
Process
Planning process to implement LS screening
Champions, opinion leaders, and other
stakeholders
Tracking and feedback processes for LS
screening
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purpose of describing contextual variation associated
with where, when, and under which conditions different
processes for implementing or improving LS screening
might be successful [47]. The result will be a descriptive
summary of patterns in variations across sites, which will
provide the basis for selecting conditions for inclusion in
the analyses for Aim 2.
Configurational comparative methods (CCM), such as
Qualitative Comparative Analysis (QCA) and coinci-
dence analysis (CNA) are particularly suitable analytic
techniques for studying causal complexity in
organizational implementation (e.g. multiple conditions
may combine in various ways to cause the same
outcome) [19, 38, 48–50]. CNA was selected for use in
our study because, unlike QCA, it uses a different
minimization algorithm that can identify underlying
causal chains [51]. This is useful because we anticipate
the presence or absence of some contextual conditions
may impact one or more combinations of other context-
ual or implementation conditions that are minimally
sufficient and necessary for the outcome under investi-
gation. Data analyses for Aim 2 will consist of 4 main
steps [38]: 1) code data for context and implementation
conditions (CFIR constructs), 2) code implementation
outcomes, 3) calibrate conditions and outcomes to
create data matrix and 4) conduct CNA and interpret
solutions to create a model of minimally sufficient and
necessary conditions for defined outcomes (Fig. 1).
Coding LS screening contextual and implementation
conditions (step 1)
All patient and organizational stakeholder interviews
will be digitally recorded and transcribed verbatim.
Transcripts will be uploaded into Atlas.ti (www.atlas-
ti.com) for qualitative analysis. Transcripts will be ini-
tially coded using an a priori codebook developed
from the semi-structured interview guides, interview
summaries, and CFIR constructs. This first round of
coding (Aim 1) will look for description of LS screen-
ing procedures, process of implementing LS screen-
ing, individuals involved and inner or outer setting as
shown in Table 2. Emergent (de novo) codes will be
added to any other relevant sections of transcript text
not fitting the a priori codes. This coding will be an
iterative process involving team members independ-
ently coding 2–3 transcripts at a time, then discussing
their coding to adjust the codebook and subsequently
to group codes into categories or themes. This
process will continue until the code list is static, all
transcripts are coded, and the categories and themes
are finalized. Additional codes will note whether con-
textual conditions were reported to impact the site’s
implementation processes or procedures and how. A
minimum of two researchers will independently code
and resolve disputes by consensus until all conditions
and impact are coded. Coding will follow protocols
detailed in the CFIR technical assistance website [47]
.
Fig. 1 Configurational Comparative Method Conceptual Model and Analytic Approach
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Coding implementation outcomes (step 2)
Two implementation outcomes will be examined: [1] im-
plementation of any type of LS screening and [2] optimal
LS screening implementation. As noted above, conditions
for optimal implementation include: implementation or
maintenance of any systematic LS screening without limi-
tations; quality tracking to confirm testing of all tumors
and disclosure of all positive screens, and systems for facili-
tating patient follow-through with confirmatory gene
sequencing. An additional file (see Additional file 2) shows
how the domains and constructs of the CFIR will be
utilized to code the stakeholder information from each site.
Sites conducting any tumor screening on all or a clearly
defined subset of endometrial and/or colorectal tumors will
be scored 1 and those that have not yet implemented rou-
tine screening will be scored 0 for the first implementation
outcome (Sites with no program in Table 1 vs. sites with
any type of program). Using data from interview tran-
scripts, site summaries, and the ability of sites to easily ac-
cess numbers of patients screened, proportion who screen
positive and proportion of those who follow-through with
confirmatory testing and counseling. At least two members
of the research team will independently code the second
implementation outcome on a scale of 0 (tumor testing
with no follow-up procedures) to 5 (fully-functioning
tumor screening with facilitation and confirmation of
germline testing). Coding conflicts will be resolved as
described previously.
Selecting and calibrating conditions and outcomes to create
a data matrix (step 3)
Following standard practices for CCM, we will select which
conditions to include using theoretical and empirical
knowledge of the cases [52–54]. To complete this task at
least two members of the research team will review the
coded data and select a set of approximately 4 to 8 condi-
tions hypothesized to impact each outcome. Final consen-
sus will be reached through discussion among coders and
other research team members who have substantive ex-
perience with LS screening. Our second implementation
outcome and any non-binary conditions will systematically
be calibrated using theoretical knowledge and recom-
mended practices in order to indicate the degree to which
the outcome or condition is present or absent [52, 54]. The
calibrated conditions and outcomes for each site will be
compiled into a numerical data matrix for use in conduct-
ing coincidence analysis (CNA).
Conducting coincidence analyses (step 4)
Coincidence analyses (CNA) will be conducted following
standard procedures [51–54] using the CNA package in R
(www.R-project.org) with the main goal of identifying
causal chains of conditions that are minimally sufficient
and necessary for each of the two main implementation
outcomes [55]. Additional CNA will be conducted to
identify which contextual conditions (if any) contribute to
variability in implementation processes or procedures that
are hypothesized or have previously been shown to be
more efficient, cost-effective, or result in better patient
ascertainment and completion of confirmatory genetic
testing [19, 29, 30, 33–35].
The resulting CNA solutions will be interpreted by the
research team to identify implications for optimal LS
screening implementation. This will be combined with
the economic analysis data from Aim 3 to form the basis
for the toolkit to help organizational decision makers
determine what implementation strategies are more
likely to work in optimizing screening given their
organizational context.
Procedures aim 3
In Aim 3 we will calculate expected outcomes central to
evaluation of effectiveness and efficiency of LS screening
in CRC and endometrial cancer (EC) patient popula-
tions. Previously developed models [29, 30] will be
modified and updated based on recent developments,
current evidence and guidelines. Models will be popu-
lated using local data to reflect site-specific conditions
as determined from data collected from study site stake-
holder interviews in Aim 1.
We will construct decision tree-type analytic models
in Excel© software (Microsoft, Inc., Redmond, Wash.),
with the @Risk© software add-on for Excel (Palisade,
Inc., Ithaca, NY) to enable various complex analytic
procedures. The decision analytic team will construct
multiple decision tree models to represent all LS
screening protocols the team considers currently
viable. Model variables include estimates of annual
incident CRC and EC cases by age strata, LS preva-
lence or the assumption of an equivalent rate for all
populations, and cost of tests included in screening
protocols from each site to populate decision analytic
models. When institutional cost is not available, alter-
native methods such as the average test cost based on
costs reported by other participating clinical sites,
regional test cost figures if publicly available from
testing companies, or Medicare reimbursement rates
will be used. Finally, reliable estimates of site-specific
LS prevalence may not be available; therefore, this
model parameter may be estimated from the most
current estimates for U.S. populations [56]. Because
clinical sites, and scientific evidence are dynamic, we
do not expect organizational resources, testing costs,
or LS screening guidelines to stay static. Therefore,
the decision analytic models developed will be
designed in such a way to facilitate ongoing use and
modification by organizations.
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Analyses aim 3
For base-case and sensitivity analyses, the decision analytic
models will calculate, for each site and in CRC and EC vir-
tual cohorts (e.g. 500 cases per year): (1) sensitivity and
specificity of each LS screening protocol in identifying LS
cases including number of LS cases expected to be identi-
fied, (2) total costs for each screening protocol, (3) cost per
CRC and EC case-screened, (4) cost-per LS index case
identified, (5) incremental differences between guideline-
based screening protocols including costs and LS cases
identified, (6) and patient adherence to each screening
protocol including number of CRC and EC cases lost to
follow up. Additional modeling of different LS screening
age cut-off policies using local-level data will be conducted
for each site. Models will provide objective metrics, driven
by local data, of the impact of applying age-cutoffs in LS
screening implementation.
Procedures aim 4
Data from Aims 1, 2, and 3 will be used to generate a
working organizational toolkit to guide implementation,
maintenance, and optimization of LS screening. Additional
information will be collected over the entire project period
from monthly project meetings, communications from site
investigators, pertinent data regarding site-specific screen-
ing changes, and external evidence or guideline changes
for LS screening. These data will be recorded in a pro-
ject specific database created for tracking such informa-
tion related to implementation [57]. This tracking
database will provide important information for the
toolkit development should any sites begin to imple-
ment LS screening based on being interviewed for Aim
1, but prior to receiving the toolkit.
The organizational toolkit will be created based on the
CFIR conceptual framework, the in-depth knowledge of
LS screening programs and contextual factors of health-
care systems from Aim 1, the cross-site comparison and
CNA results from Aim 2, and economic evaluation by
decision analytic modeling with local data from Aim 3.
This toolkit will be disseminated to all sites through site
investigators and the tracking database will record to
whom it is distributed, questions asked by those receiving
the toolkit, and any immediate actions taken by the site.
Six months after distribution of the toolkit, additional
qualitative interviews will be conducted with up to 5
organizational stakeholders at each site using the same
processes described for Aim 1. Stakeholders from sites
without LS screening and those with sub-optimal imple-
mentation will be interviewed about the utility of the tool
to facilitate implementation and improvement. Stake-
holders from sites with optimally implemented programs
will be interviewed about the utility of the tool for im-
provement or adaptation to emerging evidence. The
interview guide for this aim will be developed by the re-
search team in parallel with the development of the
toolkit.
Analyses aim 4
Interviews will be conducted, transcribed, and coded as
described for Aim 1. Interviews will be coded for infor-
mation on to whom the organizational toolkit was dis-
tributed at each site, questions that were asked by key
stakeholders, and whether and how the toolkit was used
by organizational decision makers to facilitate LS screen-
ing implementation and/or improvement.
Discussion
Dissemination
The final organizational toolkit for LS screening imple-
mentation, maintenance, and improvement will be modi-
fied based on the information learned throughout the
study and from the pilot distribution to all study sites. The
final product will include descriptions of most commonly
included stakeholders and general processes needed for
optimal LS screening, directions for processes and proto-
cols that are more likely to work by contextual factors
identified, and a generic decision analytic model for costs
and effectiveness related to available LS screening proto-
cols. This organizational toolkit will have an intuitive
interface that allows for the input of local parameters for
use by organizational decision-makers. This toolkit will be
distributed through the Lynch Syndrome Screening Net-
work (LSSN; www.lynchscreening.net) and through other
channels that may be identified.
Innovation
Through in-depth assessment of contextual conditions
impacting LS screening implementation across an unpre-
cedented number of sites representing diverse healthcare
systems, geographies, and patient populations served, this
study will provide significant information for the Precision
Prevention and Early Detection Working Group of the
Blue Ribbon Panel to successfully address the Cancer
Moonshot [9], and for the working group of National
Academies of Sciences, Engineering, and Medicine
(NASEM) to successfully facilitate their goal of broadly
implementing LS screening [58]. This study will also con-
tribute to implementation science more generally, as it
combines multiple methods to extend beyond the typical
“lessons learned” approach and utilizes a relatively new
analytic approach to illuminate minimally necessary and
sufficient conditions for LS screening implementation in
different organizational contexts. Another innovation of
this study is our ability to provider tailored information to
each site by combining key stakeholder information with
business case decision analytic models that can be popu-
lated with local, real-world data. The relevance of general
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societal cost to organizational decision-making has been
questioned [59, 60] and prior studies indicate that
organization-specific costs to screen and to detect LS
cases for different protocols is critical information for
health systems to make decisions about LS screening
implementation [28–30].
To our knowledge, no studies have synthesized in-depth
cross-site comparison of context, barriers and facilitators
with local business case analyses into a comprehensive tool-
kit for organizations implementing and optimizing LS
screening programs. Most studies to date have focused on
strategies for initial implementation, rather than mainten-
ance and improvement in the face of organizational context
or changes in evidence. This study will fill that gap and
provide insights into successful implementation in the era
of precision medicine where evidence is evolving and costs
and opportunities for genomic testing are rapidly changing.
Limitations and challenges
Healthcare systems and evidence are dynamic; therefore,
it is possible that any of the participating sites may imple-
ment LS screening during the course of the study, or that
sites currently implementing LS screening may optimize
their programs prior to receiving the toolkit. This possibil-
ity may decrease the diversity of our sites in contextual or
implementation conditions or outcomes; thus, changes
will be tracked to ensure the integrity of the analyses.
Additionally, new evidence [61] and declining costs of se-
quencing may lead to the replacement of currently recom-
mended LS screening protocols with tumor sequencing or
even germline sequencing of all newly diagnosed cancer
patients. Because economic evaluation is an integral part
of this study and direct sequencing cost comparison will
be included in the organizational decision-making guide,
this changing evidence can easily be re-evaluated by each
organization’s decision-makers over time. Because this
study is specifically designed to collect cost and contextual
information throughout the course of the study, we will
utilize changes made at any site over the course of the
study as data to inform implementation, maintenance, and
adaptation broadly. Therefore, this study will not only
result in a toolkit to guide LS screening implementation in
an era of dynamic and changing evidence and costs, but
may also broadly demonstrate for the field of implementa-
tion science methods for conducting research in the
real-world that are focused on optimization, maintenance,
and adaptation to new evidence.
Summary and impact
This study addresses a major unmet need identified by the
Blue Ribbon Panel to achieve the goals of the Cancer
Moonshot and to improve our understanding of clinical
implementation of complex interventions [9]. The over-
arching goal of this study is to determine factors associated
with variations in LS screening implementation across mul-
tiple healthcare systems and to provide the organizational
decision tools, or “recipes,” for implementation success in
light of different organizational contexts and costs. The
organizational toolkit that we produce will help health sys-
tems to maintain and optimize LS screening programs in
the face of changing costs and evidence. Our toolkit based
on implementation science may be adapted to help in
implementing evidence-based screening for other genomic
conditions or for implementing other types of complex
genomics interventions into healthcare systems.
Additional Files
Additional file 1: Suggested Optimal Lynch Syndrome Screening
Program Protocol. This file shows the flow diagram of the suggested
optimal design for a LS screening program protocol based on current
guidelines. (PDF 78 kb)
Additional file 2: Analytic Model Showing CFIR Constructs by Domain
for Coding. This file diagrams how the key stakeholder interview data will
be coded by CFIR constructs and domains, and how we will analyze
across cases to determine barriers and facilitators of LS program
development. (PDF 104 kb)
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